U.S. - Egypt Joint Clinical Study Blocked by the NYSDOH
New York, January 15, 2008 - A landmark study aimed at Egypt's hepatitis C pandemic recruiting the collaboration of the National Research Centre (NRC) in Cairo, Egypt, and Medizone International, Inc., a U.S. public company engaged in developing complementary therapies for hepatitis C, was blocked by the NYSDOH (New York State Department of Health).
According to Dr. Grard Sunnen, former president and director of research for Medizone, the NYSDOH stopped the study at a time when all contracts were signed and study volunteers in Egypt had already been selected. ''The motives are clear. The NYSDOH has a history of strongly suppressing complementary therapies. Also, special interests are involved, potent economic forces fighting to keep the status quo on established pharmaceutical pipelines," he said.
In Egypt, hepatitis C prevalence is the highest in the world. A vaccination program gone awry provides a partial explanation for this massive infection rate. "The NRC, responding to this huge public health crisis, contacted Medizone seeking its immune activation technology. Conventional drug therapies are prohibitively costly for such a large target population and are inordinately prone to failure and to serious side effects. The Medizone process, by contrast, is considerably less onerous," Dr. Sunnen added.
"The rewards of this (failed) research would have extrapolated far beyond the treatment of hepatitis C. Immune function enhancement is a bonus for a host of diseases and could thus well complement current treatment options for several major pathogenic viruses," said Dr. Sunnen.
"Special interests and other agendas can all too easily kill innovative medical research," Dr. Sunnen concluded, adding, "when that happens, the public interest invariably suffers and a little humanity is removed from each one of us."
CONTACT INFORMATION:
Gerard Sunnen, M.D.
Ozonics International, LLC
200 East 33 Street, Suite 26J
New York, NY 10016-4831 USA
Tel. 1-212-6790679 / Fax 1-212-6798008
www.ozonicsint.com
GSunnen@aol.com
According to Dr. Grard Sunnen, former president and director of research for Medizone, the NYSDOH stopped the study at a time when all contracts were signed and study volunteers in Egypt had already been selected. ''The motives are clear. The NYSDOH has a history of strongly suppressing complementary therapies. Also, special interests are involved, potent economic forces fighting to keep the status quo on established pharmaceutical pipelines," he said.
In Egypt, hepatitis C prevalence is the highest in the world. A vaccination program gone awry provides a partial explanation for this massive infection rate. "The NRC, responding to this huge public health crisis, contacted Medizone seeking its immune activation technology. Conventional drug therapies are prohibitively costly for such a large target population and are inordinately prone to failure and to serious side effects. The Medizone process, by contrast, is considerably less onerous," Dr. Sunnen added.
"The rewards of this (failed) research would have extrapolated far beyond the treatment of hepatitis C. Immune function enhancement is a bonus for a host of diseases and could thus well complement current treatment options for several major pathogenic viruses," said Dr. Sunnen.
"Special interests and other agendas can all too easily kill innovative medical research," Dr. Sunnen concluded, adding, "when that happens, the public interest invariably suffers and a little humanity is removed from each one of us."
CONTACT INFORMATION:
Gerard Sunnen, M.D.
Ozonics International, LLC
200 East 33 Street, Suite 26J
New York, NY 10016-4831 USA
Tel. 1-212-6790679 / Fax 1-212-6798008
www.ozonicsint.com
GSunnen@aol.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.